EBIT: Income before interest and taxes.
Gain Therapeutics, Inc. (GANX) had EBIT of $-4.79M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-5.28M |
|
-- |
|
-- |
|
$4.79M |
|
$-4.79M |
|
$0.05M |
|
$-4.74M |
|
$-4.74M |
|
$-5.28M |
|
$-5.28M |
|
$-5.28M |
|
$-5.28M |
|
|
EBIT |
$-4.79M |
$-4.76M |
|
35.00M |
|
35.00M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$10.52M |
|
$0.09M |
|
$0.45M |
|
$10.97M |
|
$4.17M |
|
$0.30M |
|
$0.89M |
|
$5.06M |
|
$5.91M |
|
$5.91M |
|
$5.91M |
|
35.98M |
|
| Cash Flow Statement Financials | |
$-13.85M |
|
$0.00M |
|
$11.90M |
|
$10.42M |
|
$8.84M |
|
$-1.57M |
|
$1.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.52 |
|
-- |
|
-- |
|
0.05 |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-89.42% |
|
-89.42% |
|
-48.16% |
|
-85.12% |
|
$0.16 |
|
$-0.40 |
|
$-0.40 |
|